Technologies

In order to address the severity of SARS-CoV-2 pandemic, we have produced a humanized monoclonal antibody (7F7) neutralizing SARS-CoV-2, B.1.1.7, B.1.351, B.1.1.28.1 and B.1.617.2 variants by spike protein immunization, mouse splenic fusion, hybridoma screening, and antibody humanization by CDR grafting. This 7F7 neutralizing antibody is further characterized by receptor-binding inhibition, neutralization, and antibody kinetic assays. The antibody is epitope mapped against spike domain proteins for antigen specificity. The Fc region of the antibody is mutated to minimize antibody-dependent enhancement (ADE) immune response.